Johnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy’s failure in two mid-stage trials.

The company said that JNJ-4804, a combination of the blockbuster drugs Tremfya …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844